Research map: Low‐Dose Antiangiogenic Therapy With Different Chemotherapy Backbones Among Patients With Heavily Pretreated Metastatic Breast Cancer

Back to the article

Papers in this map

  1. Tumor Angiogenesis: Therapeutic Implications · Louis M. Sherwood · 1971 · 10246 citations · Cited by this paper
  2. mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics · 2025 · Related
  3. Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer · Kathy D. Miller · 2007 · 3088 citations · Cited by this paper
  4. Individualized Analysis of Nipple‐Sparing Mastectomy Versus Modified Radical Mastectomy Using Deep Learning · 2025 · Related
  5. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges · Dai Fukumura · 2018 · 2048 citations · Cited by this paper
  6. Identification and Evaluation of the Urinary Microbiota Associated With Bladder Cancer · 2025 · Related
  7. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer · Nicholas J. Robert · 2011 · 1076 citations · Cited by this paper
  8. The Efficacy and Safety of Pegylated Liposomal Doxorubicin‐Based Neoadjuvant Chemotherapy in Children With Osteosarcoma: A Retrospective Real‐World Study · 2025 · Related
  9. Ten years of anti-vascular endothelial growth factor therapy · Napoleone Ferrara · 2016 · 1050 citations · Cited by this paper
  10. Combining Small‐Molecular Compounds With CAR T‐Cell Therapy: Novel Strategies for Enhanced Cancer Immunotherapy · 2026 · Related
  11. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer · Baohui Han · 2018 · 634 citations · Cited by this paper
  12. Coexistent Pulmonary Tuberculosis and Lung Cancer: An Analysis of Incidence Trends, Financial Burdens and Influencing Factors · 2025 · Related
  13. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors · Yongkun Sun · 2016 · 436 citations · Cited by this paper
  14. Statins in Breast Cancer Therapy: Mechanistic Insights and Emerging Evidence · 2026 · Related
  15. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer · Adam Brufsky · 2011 · 425 citations · Cited by this paper
  16. Identification of Chondroitin Polymerizing Factor as a Biomarker for Colorectal Cancer by the Human Villi Development Model · 2025 · Related
  17. Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters · Yan‐jun Mi · 2010 · 350 citations · Cited by this paper
  18. Extrachromosomal Circular DNA as a Cancer Biomarker: From Diagnosis to Treatment · 2025 · Related
  19. Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma · Yihebali Chi · 2018 · 339 citations · Cited by this paper
  20. Efficacy and Safety of Anlotinib‐Based Regimens in Metastatic Breast Cancer: A Multicenter Real‐World Study · 2025 · Related
  21. Triple negative breast cancer: A thorough review of biomarkers · Jessé Lopes da Silva · 2019 · 292 citations · Cited by this paper
  22. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer · Xichun Hu · 2014 · 272 citations · Cited by this paper
  23. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial · Shukui Qin · 2021 · 262 citations · Cited by this paper
  24. Multicenter phase II study of Apatinib in non-triple-negative metastatic breast cancer · Xichun Hu · 2014 · 240 citations · Cited by this paper
  25. Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers · Lesley J. Scott · 2018 · 239 citations · Cited by this paper
  26. Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer · Chunfeng Xie · 2021 · 215 citations · Cited by this paper
  27. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy · Amye Juliet Tevaarwerk · 2012 · 196 citations · Cited by this paper
  28. Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment · Guihong Liu · 2021 · 192 citations · Cited by this paper
  29. Locally recurrent or metastatic breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up · Fátima Cardoso · 2009 · 126 citations · Cited by this paper
  30. Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells · Xiu-zhen Tong · 2011 · 118 citations · Cited by this paper
  31. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer · Yongkun Sun · 2018 · 115 citations · Cited by this paper
  32. BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study · Peter Andreas Fasching · 2018 · 108 citations · Cited by this paper
  33. Anlotinib potentiates anti‐PD1 immunotherapy via transferrin receptor‐dependent CD8 + T‐cell infiltration in hepatocellular carcinoma · Fei Song · 2024 · 55 citations · Cited by this paper
  34. Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study · Jiehai Yu · 2024 · 52 citations · Cited by this paper
  35. Novel Adverse Events of Bevacizumab in the US FDA Adverse Event Reporting System Database · Behrooz K Shamloo · 2012 · 42 citations · Cited by this paper
  36. Anlotinib enhanced CD8+ T cell infiltration via induction of CCL5 improves the efficacy of PD-1/PD-L1 blockade therapy in lung cancer · Jie Luo · 2024 · 41 citations · Cited by this paper
  37. First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial · Huizi Sha · 2024 · 39 citations · Cited by this paper
  38. Neoadjuvant camrelizumab (an anti-PD-1 antibody) plus chemotherapy or apatinib (a VEGFR-2 inhibitor) for initially unresectable stage II–III non-small-cell lung cancer: a multicentre, two-arm, phase 2 exploratory study · Haoran Xia · 2024 · 36 citations · Cited by this paper
  39. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial · Doudou Li · 2022 · 32 citations · Cited by this paper

Source: OpenAlex (CC0)